ALKBH5 and breast cancer: Concretely, ALKBH5 acts as an oncogene in glioblastoma (Zhang et al., 2017), acute myeloid leukemia (Shen et al., 2020), breast cancer (Zhang et al., 2016), and ovarian carcinoma (Jiang et al., 2020), while functioning as a tumor suppressor in lung cancer (Zhang et al., 2021), hepatocellular carcinoma (Chen et al., 2020), and osteosarcoma (Yuan et al., 2021).